Results 81 to 90 of about 1,701 (184)

Lenacapavir allosterically remodels the HIV-1 capsid

Science Advances
Abstract Lenacapavir (LEN) is a highly potent, long-acting HIV-1 capsid inhibitor that holds exceptional promise for pre-exposure prophylaxis. LEN causes the mature viral capsid to rupture and lose integrity, but the underlying mechanism has been unclear.
Nayara F. B. dos Santos, Jacob A. Lewis, Mason Hansen, Miguel J. B. Pereira, Devin E. Christensen, Wesley I. Sundquist, Barbie K. Ganser-Pornillos, Owen Pornillos   +7 more
openaire   +4 more sources

A Systematic Review of Barriers and Facilitators to Long-Acting HIV Pre-Exposure Prophylaxis Uptake among Key Populations in Nigeria: Implications for Lenacapavir.

Panorama of Emergency Medicine
Background: Long-acting injectable pre-exposure prophylaxis (LAI-PrEP) offers a promising strategy for HIV prevention by addressing adherence challenges associated with daily oral pre-exposure prophylaxis (PrEP).
Adeyemi Ogedengbe Omoge, Modupe Oluwatimileyin Omoge, Oluwabunmi Bridget Erinsakin, Oluwafemi Olumide Oyetunji   +3 more
doaj   +1 more source

Efficacy and Safety of Lenacapavir for HIV Treatment and Prevention: A Systematic Review

Lenacapavir, a first-in-class capsid inhibitor, represents a significant innovation due to its unique mechanism of action, targeting multiple stages of the viral replication cycle.
Takunda Mukuhlani
core   +1 more source

Cost thresholds for anticipated long‐acting HIV pre‐exposure prophylaxis products in Eastern and Southern Africa: a mathematical modelling study

Journal of the International AIDS Society
Introduction Affordable HIV prevention tools are needed in Eastern and Southern Africa (ESA). Several promising long‐acting pre‐exposure prophylaxis (LA‐PrEP) products are available or in development. However, ESA settings face severe healthcare resource
David Kaftan, Monisha Sharma, Danielle Resar, Masabho Milali, Edinah Mudimu, Linxuan Wu, Cory Arrouzet, Ingrida Platais, Hae‐Young Kim, Sarah Jenkins, Anna Bershteyn   +10 more
doaj   +1 more source

Structure of HIV-1 and HIV-2 CA and binding mode of lenacapavir.

(A) Structural alignment of HIV-1 and HIV-2 CA. HIV-1 CA is represented based on a crystal structure (PDB ID: 6VKV) [69], while the structure of HIV-2 CA was modeled previously using AlphaFold [82].
Gyula Hoffka (20904100), József Tőzsér (665273), Mohamed Mahdi (665270), János András Mótyán (3804706), Botond Lakatos (12478740)   +4 more
core   +1 more source

Breaking barriers for key populations in the lenacapavir era

Decoding Infection and Transmission
Despite advances in human immunodeficiency virus (HIV) prevention, key populations including men who have sex with men (MSM), sex workers, transgender individuals, people who inject drugs, and adolescent girls and young women (AGYW) continue to ...
Victor Abiola Adepoju, Abdulrakib Abdulrahim, Safayet Jamil   +2 more
doaj   +1 more source

Lenacapavir Exhibits Atropisomerism—Mechanistic Pharmacokinetics and Disposition Studies of Lenacapavir Reveal Intestinal Excretion as a Major Clearance Pathway

The Journal of Pharmacology and Experimental Therapeutics
Lenacapavir (LEN), a long-acting injectable, is the first approved human immunodeficiency virus type 1 capsid inhibitor and one of a few Food and Drug Administration-approved drugs that exhibit atropisomerism. LEN exists as a mixture of two class 2 atropisomers that interconvert at a fast rate (half-life < 2 hours) with a ratio that is stable over time
Jim Zheng, Bing Lu, Gavin Carr, Judy Mwangi, Kelly Wang, Jia Hao, Kelly McLennan Staiger, Nathan Kozon, Bernard P. Murray, Mohammad Bashir, Mark A. Gohdes, Winston C. Tse, Scott Schroeder, Michael Graupe, John O. Link, Jungjoo Yoon, Anna Chiu, William Rowe, Bill J. Smith, Raju Subramanian   +19 more
openaire   +2 more sources

Revolutionizing HIV treatment: unveiling the new frontiers of HIV capsid research

Acta Materia Medica
The HIV-1 capsid protein (CA) plays a crucial role in viral replication by orchestrating nuclear entry through interactions with host nuclear pore complexes (NPCs).
Mei Wang, Shujing Xu, Haiyong Jia, Peng Zhan   +3 more
doaj   +1 more source

Antiretroviral drugs from multiple classes induce loss of excitatory synapses between hippocampal neurons in culture

Frontiers in Pharmacology
Introduction: Antiretroviral (ARV) drugs have improved prognoses for people living with HIV. However, HIV-associated neurocognitive disorders (HAND) persist despite undetectable viral loads. Some ARVs have been linked to neuropsychiatric effects that may
Hannah M. McMullan, Benjamin M. Gansemer, Stanley A. Thayer   +2 more
doaj   +1 more source

Twice-Yearly Injectable Pre-Exposure Prophylaxis With Lenacapavir: Redefining Adherence and Access in the Global Fight Against HIV

Journal of the International Association of Providers of AIDS Care
Despite progress in human immunodeficiency virus (HIV) prevention, global targets remain unmet, with over 1.3 million new infections annually—driven by adherence challenges, stigma, and daily pill fatigue linked to oral pre-exposure prophylaxis (PrEP ...
Santosh Sah MBBS, Ureeba Iqbal MBBS, Trilok Mishra MBBS, Najeeb Ullah MBBS, Tularam Yadav MBBS   +4 more
doaj   +1 more source